62,014 Shares in Medpace Holdings, Inc. $MEDP Bought by Nuveen LLC

Key Points

• Nuveen LLC acquired a new stake in Medpace Holdings, Inc. valued at approximately $18.90 million, owning about 0.22% of the company as of their latest SEC filing.
• Medpace's shares opened at $462.14, with a market cap of $12.98 billion and a 1-year performance range between $250.05 and $501.30.
• In its recent quarterly earnings report, Medpace surpassed analysts’ expectations with $3.10 earnings per share (EPS), and has projected FY 2025 EPS guidance between $13.760 and $14.53.

Nuveen LLC acquired a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 62,014 shares of the company's stock, valued at approximately $18,895,000. Nuveen LLC owned 0.22% of Medpace as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also modified their holdings of MEDP. Polen Capital Management LLC boosted its stake in shares of Medpace by 50.8% in the first quarter. Polen Capital Management LLC now owns 24,466 shares of the company's stock worth $7,455,000 after buying an additional 8,243 shares during the last quarter. Invesco Ltd. boosted its stake in shares of Medpace by 9.4% in the first quarter. Invesco Ltd. now owns 1,186,768 shares of the company's stock worth $361,596,000 after buying an additional 102,015 shares during the last quarter. Benjamin Edwards Inc. boosted its stake in shares of Medpace by 3.1% in the first quarter. Benjamin Edwards Inc. now owns 1,201 shares of the company's stock worth $366,000 after buying an additional 36 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Medpace by 32.3% in the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 86,566 shares of the company's stock worth $26,376,000 after buying an additional 21,150 shares during the last quarter. Finally, Zions Bancorporation National Association UT purchased a new stake in shares of Medpace in the first quarter worth about $2,710,000. 77.98% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Medpace

In other news, CEO August J. Troendle sold 48,487 shares of the firm's stock in a transaction on Monday, July 28th. The stock was sold at an average price of $451.69, for a total transaction of $21,901,093.03. Following the completion of the transaction, the chief executive officer directly owned 962,615 shares in the company, valued at $434,803,569.35. This trade represents a 4.80% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Susan E. Burwig sold 7,500 shares of the firm's stock in a transaction on Monday, July 28th. The stock was sold at an average price of $450.14, for a total value of $3,376,050.00. Following the transaction, the vice president owned 57,500 shares of the company's stock, valued at approximately $25,883,050. This represents a 11.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 114,450 shares of company stock valued at $51,791,251. Corporate insiders own 20.30% of the company's stock.

Analyst Ratings Changes

MEDP has been the topic of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft increased their price target on Medpace from $270.00 to $430.00 and gave the stock a "hold" rating in a research report on Wednesday, July 23rd. UBS Group downgraded Medpace from a "neutral" rating to a "sell" rating and increased their price target for the stock from $300.00 to $305.00 in a research report on Tuesday, July 29th. Cowen downgraded Medpace from a "buy" rating to a "sell" rating in a research report on Wednesday, July 23rd. Robert W. Baird increased their price target on Medpace from $313.00 to $490.00 and gave the stock a "neutral" rating in a research report on Wednesday, July 23rd. Finally, Barclays raised their target price on Medpace from $300.00 to $450.00 and gave the company an "equal weight" rating in a research report on Wednesday, July 23rd. Two investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Reduce" and a consensus target price of $406.60.

Medpace Stock Up 2.3%

Shares of NASDAQ MEDP traded up $10.30 during midday trading on Friday, hitting $463.64. The stock had a trading volume of 328,935 shares, compared to its average volume of 424,882. The company has a market capitalization of $13.02 billion, a PE ratio of 34.47, a P/E/G ratio of 2.92 and a beta of 1.42. The stock has a 50 day simple moving average of $378.86 and a 200-day simple moving average of $335.05. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $501.30.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings results on Monday, July 21st. The company reported $3.10 EPS for the quarter, beating the consensus estimate of $3.00 by $0.10. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The firm had revenue of $603.31 million during the quarter, compared to analysts' expectations of $537.70 million. During the same quarter last year, the firm earned $2.75 earnings per share. The business's revenue for the quarter was up 14.2% on a year-over-year basis. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. As a group, analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.